×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ASND – ascendis pharma a/s - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ASND
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/20
09:28 pm
asnd
Ascendis Pharma Trial Wins And Valuation Gap Draw Investor Attention [Yahoo! Finance]
Neutral
Report
Ascendis Pharma Trial Wins And Valuation Gap Draw Investor Attention [Yahoo! Finance]
3/17
09:05 am
asnd
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 [Yahoo! Finance]
Low
Report
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 [Yahoo! Finance]
3/17
08:30 am
asnd
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
Low
Report
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
3/16
10:58 am
asnd
Ascendis Pharma A/S (ASND) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Low
Report
Ascendis Pharma A/S (ASND) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
3/16
08:00 am
asnd
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
Low
Report
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
3/12
08:48 am
asnd
Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy
Low
Report
Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy
3/5
05:03 pm
asnd
Ascendis Pharma A/S (ASND) had its "buy" rating reaffirmed by Bank of America Corporation.
Low
Report
Ascendis Pharma A/S (ASND) had its "buy" rating reaffirmed by Bank of America Corporation.
3/4
10:52 pm
asnd
Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference [Yahoo! Finance]
Low
Report
Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/11/2026
04:01 pm
asnd
ascendis pharma a/s - american depositary shares
MISS
Report
-1.5%
ascendis pharma a/s - american depositary shares
11/12/2025
04:01 pm
asnd
ascendis pharma a/s - american depositary shares
MISS
Report
3.1%
ascendis pharma a/s - american depositary shares
8/7/2025
04:01 pm
asnd
ascendis pharma a/s - american depositary shares
BEAT
Report
0.6%
ascendis pharma a/s - american depositary shares
5/1/2025
04:01 pm
asnd
ascendis pharma a/s - american depositary shares
MISS
Report
2.7%
ascendis pharma a/s - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/18
06:15 pm
asnd
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: Fairey William
Low
Report
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: Fairey William
3/18
06:14 pm
asnd
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: IMANI SIHAM
Low
Report
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: IMANI SIHAM
3/18
06:14 pm
asnd
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: SMITH SCOTT THOMAS
Low
Report
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: SMITH SCOTT THOMAS
3/18
06:13 pm
asnd
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: JENSEN MICHAEL WOLFF
Low
Report
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: JENSEN MICHAEL WOLFF
3/18
06:12 pm
asnd
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: Bodenhoff Mads
Low
Report
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: Bodenhoff Mads
3/18
06:12 pm
asnd
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG
Low
Report
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG
3/18
06:11 pm
asnd
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: Morrison Lisa
Low
Report
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: Morrison Lisa
3/18
06:10 pm
asnd
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: SPROGOE KENNETT
Low
Report
Form 3 Ascendis Pharma A/S For: Mar 18 Filed by: SPROGOE KENNETT
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/20
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Oppenheimer Holdings Inc. from $199.00 to $219.00. They now have an "outperform" rating on the stock.
9.1%
11/18 Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results 6.3%
6/3 Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $223.00 price target on the stock, up previously from $219.00. 6.0%
6/14 Form 6-K Ascendis Pharma A/S For: Jun 14 5.5%
11/22 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.3%
12/17 Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Morgan Stanley from $134.00 to $140.00. They now have an "overweight" rating on the stock. 4.6%
12/25 Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.1%
10/10 Form 6-K Ascendis Pharma A/S For: Oct 10 3.8%
11/20 Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT [Yahoo! Finance News] 3.7%
4/14 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.6%
11/18 Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results 6.3%
6/3 Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $223.00 price target on the stock, up previously from $219.00. 6.0%
6/14 Form 6-K Ascendis Pharma A/S For: Jun 14 5.5%
11/22 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.3%
12/17 Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Morgan Stanley from $134.00 to $140.00. They now have an "overweight" rating on the stock. 4.6%
12/25 Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.1%
10/10 Form 6-K Ascendis Pharma A/S For: Oct 10 3.8%
11/20 Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT [Yahoo! Finance News] 3.7%
4/14 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.6%
TOP News Decliners
6/26
Form 6-K Ascendis Pharma A/S For: Jun 26
-9.8%
9/26 Ascendis Pharma A/S Announces Upcoming Investor Presentation in October -7.5%
4/20 Form 6-K Ascendis Pharma A/S For: Apr 20 -5.8%
5/30 Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.4%
8/29 Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.2%
3/31 Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD -5.0%
11/15 Form 6-K Ascendis Pharma A/S For: Nov 15 -4.2%
7/1 Form 6-K Ascendis Pharma A/S For: Jul 01 -3.9%
4/2 Ascendis Pharma A/S (ASND) Q4 2019 Earnings Call Transcript [The Motley Fool] -3.6%
6/10 Form SC 13G/A Ascendis Pharma A/S Filed by: PRICE T ROWE ASSOCIATES INC /MD/ -3.5%
9/26 Ascendis Pharma A/S Announces Upcoming Investor Presentation in October -7.5%
4/20 Form 6-K Ascendis Pharma A/S For: Apr 20 -5.8%
5/30 Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.4%
8/29 Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.2%
3/31 Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD -5.0%
11/15 Form 6-K Ascendis Pharma A/S For: Nov 15 -4.2%
7/1 Form 6-K Ascendis Pharma A/S For: Jul 01 -3.9%
4/2 Ascendis Pharma A/S (ASND) Q4 2019 Earnings Call Transcript [The Motley Fool] -3.6%
6/10 Form SC 13G/A Ascendis Pharma A/S Filed by: PRICE T ROWE ASSOCIATES INC /MD/ -3.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: